{"id":"NCT01622231","sponsor":"GlaxoSmithKline","briefTitle":"Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis","officialTitle":"Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2012-06-19","resultsPosted":"2013-08-12","lastUpdate":"2017-01-09"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rhinitis"],"interventions":[{"type":"DRUG","name":"Fluticasone furoate","otherNames":[]}],"arms":[{"label":"GW685698X","type":"EXPERIMENTAL"}],"summary":"Safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \\< 15 years with perennial allergic rhinitis will be evaluated. And secondarily, efficacy and systemic exposure of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \\< 15 years with perennial allergic rhinitis will also be evaluated.","primaryOutcome":{"measure":"Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)","timeFrame":"From the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks)","effectByArm":[{"arm":"GW685698X 55 μg QD","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["Nasopharyngitis","Acute sinusitis"]}}